FDA Gives AveXis Thumbs Up to Launch Gene Therapy Study in SMA Type 2 – SMA News Today
SMA News Today |
FDA Gives AveXis Thumbs Up to Launch Gene Therapy Study in SMA Type 2
SMA News Today The U.S. Food and Drug Administration (FDA) has given AveXis the green light to launch a Phase 1 study of its gene therapy, AVXS-101, in children with spinal muscular atrophy (SMA) Type 2. In contrast to the company's earlier study in Type 1 SMA … |
